Dimethyl Fumarate Patent Expiration

Dimethyl Fumarate is Used for treating autoimmune diseases such as multiple sclerosis and relapsing forms before and after administering an inactive vaccine. It was first introduced by Biogen Inc in its drug Tecfidera on Mar 27, 2013. 17 different companies have introduced drugs containing Dimethyl Fumarate.


Dimethyl Fumarate Patents

Given below is the list of patents protecting Dimethyl Fumarate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tecfidera US10391160 Dimethyl fumarate and vaccination regimens Mar 13, 2035 Biogen Inc
Tecfidera US10555993 Dimethyl fumarate and vaccination regimens Mar 13, 2035 Biogen Inc
Tecfidera US10959972 Methods of treating multiple sclerosis Nov 16, 2035 Biogen Inc
Tecfidera US10994003 Dimethyl fumarate and vaccination regimens Mar 13, 2035 Biogen Inc
Tecfidera US11007166 Methods of treating multiple sclerosis Nov 16, 2035 Biogen Inc
Tecfidera US11007167 Methods of treating multiple sclerosis Nov 16, 2035 Biogen Inc
Tecfidera US11129806 Methods of treating multiple sclerosis Nov 16, 2035 Biogen Inc
Tecfidera US11246850 Methods of treating multiple sclerosis Nov 16, 2035 Biogen Inc
Tecfidera US6509376 Utilization of dialkyfumarates Oct 29, 2019

(Expired)

Biogen Inc
Tecfidera US7320999 Dimethyl fumarate for the treatment of multiple sclerosis May 18, 2020

(Expired)

Biogen Inc
Tecfidera US7619001 Utilization of dialkylfumarates Apr 01, 2018

(Expired)

Biogen Inc
Tecfidera US7803840 Utilization of dialkylfumarates Apr 01, 2018

(Expired)

Biogen Inc
Tecfidera US8399514 Treatment for multiple sclerosis Feb 07, 2028 Biogen Inc
Tecfidera US8524773 Utilization of dialkylfumarates Apr 01, 2018

(Expired)

Biogen Inc
Tecfidera US8759393 Utilization of dialkylfumarates Jul 04, 2018

(Expired)

Biogen Inc


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dimethyl Fumarate's patents.

Given below is the list recent legal activities going on the following patents of Dimethyl Fumarate.

Event Date Patent/Publication
Patent litigations
Expire Patent 18 Mar, 2024 US10555993
Maintenance Fee Reminder Mailed 02 Oct, 2023 US10555993
Termination or Final Written Decision 03 Feb, 2023 US8399514
Payment of Maintenance Fee, 4th Year, Large Entity 20 Jan, 2023 US10391160
Expire Patent 31 Oct, 2022 US7803840
Expire Patent 01 Aug, 2022 US8759393
Maintenance Fee Reminder Mailed 16 May, 2022 US7803840
Patent Issue Date Used in PTA Calculation 15 Feb, 2022 US11246850
Recordation of Patent Grant Mailed 15 Feb, 2022 US11246850
Maintenance Fee Reminder Mailed 14 Feb, 2022 US8759393



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Dimethyl Fumarate Generics

Several generic applications have been filed for Dimethyl Fumarate. The first generic version for Dimethyl Fumarate was by Mylan Pharmaceuticals Inc and was approved on Aug 17, 2020. And the latest generic version is by Macleods Pharmaceuticals Ltd and was approved on Jun 26, 2024.

Given below is the list of companies who have filed for Dimethyl Fumarate generic.


1. ACCORD HLTHCARE

Accord Healthcare Inc has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.

Strength Dosage Form Availability Application Pathway TE code Launch Date
120MG capsule, delayed release Prescription ORAL AB Sep 24, 2020
240MG capsule, delayed release Prescription ORAL AB Sep 24, 2020


2. MYLAN

Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Mylan.

Strength Dosage Form Availability Application Pathway TE code Launch Date
120MG capsule, delayed release Prescription ORAL AB Aug 17, 2020
240MG capsule, delayed release Prescription ORAL AB Aug 17, 2020


3. CIPLA

Cipla Ltd has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Cipla.

Strength Dosage Form Availability Application Pathway TE code Launch Date
120MG capsule, delayed release Prescription ORAL AB Sep 24, 2020
240MG capsule, delayed release Prescription ORAL AB Sep 24, 2020


4. AMNEAL

Amneal Eu Ltd has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Amneal.

Strength Dosage Form Availability Application Pathway TE code Launch Date
120MG capsule, delayed release Prescription ORAL AB Sep 24, 2020
240MG capsule, delayed release Prescription ORAL AB Sep 24, 2020


5. LUPIN

Lupin Inc has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Lupin.

Strength Dosage Form Availability Application Pathway TE code Launch Date
120MG capsule, delayed release Prescription ORAL AB Oct 5, 2020
240MG capsule, delayed release Prescription ORAL AB Oct 5, 2020


6. TWI PHARMS

Twi Pharmaceuticals Inc has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Twi Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
240MG capsule, delayed release Prescription ORAL AB Oct 14, 2020
120MG capsule, delayed release Prescription ORAL AB Oct 14, 2020


7. SAWAI USA

Sawai Usa Inc has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Sawai Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
240MG capsule, delayed release Discontinued ORAL N/A Dec 21, 2021
120MG capsule, delayed release Discontinued ORAL N/A Dec 21, 2021


8. HETERO LABS LTD III

Hetero Labs Ltd Unit Iii has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.

Strength Dosage Form Availability Application Pathway TE code Launch Date
120MG capsule, delayed release Prescription ORAL AB Sep 24, 2020
240MG capsule, delayed release Prescription ORAL AB Sep 24, 2020


9. PRINSTON INC

Prinston Pharmaceutical Inc has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Prinston Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
120MG capsule, delayed release Prescription ORAL AB Oct 18, 2022
240MG capsule, delayed release Prescription ORAL AB Oct 18, 2022


10. AUROBINDO PHARMA

Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
120MG capsule, delayed release Prescription ORAL AB Dec 22, 2022
240MG capsule, delayed release Prescription ORAL AB Dec 22, 2022


11. MSN

Msn Laboratories Private Ltd has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Msn.

Strength Dosage Form Availability Application Pathway TE code Launch Date
120MG capsule, delayed release Prescription ORAL AB Sep 24, 2020
240MG capsule, delayed release Prescription ORAL AB Sep 24, 2020


12. ALKEM LABS LTD

Alkem Laboratories Ltd has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
120MG capsule, delayed release Prescription ORAL AB Sep 24, 2020
240MG capsule, delayed release Prescription ORAL AB Sep 24, 2020


13. SOLA PHARMS

Sola Pharmaceuticals has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Sola Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
240MG capsule, delayed release Prescription ORAL AB Mar 26, 2021
120MG capsule, delayed release Prescription ORAL AB Mar 26, 2021


14. ZYDUS PHARMS

Zydus Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Zydus Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
240MG capsule, delayed release Discontinued ORAL N/A Sep 24, 2020
120MG capsule, delayed release Discontinued ORAL N/A Sep 24, 2020


15. MACLEODS PHARMS LTD

Macleods Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
240MG capsule, delayed release Prescription ORAL AB Jun 26, 2024
120MG capsule, delayed release Prescription ORAL AB Jun 26, 2024


16. GLENMARK PHARMS LTD

Glenmark Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Dimethyl Fumarate. Given below are the details of the strengths of this generic introduced by Glenmark Pharms Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
120MG capsule, delayed release Prescription ORAL AB Oct 6, 2020
240MG capsule, delayed release Prescription ORAL AB Oct 6, 2020